1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : SPECIALTY PHARMACEUTICALS
  4. CURANEX PHARMACEUTICALS INC.
Curanex Pharmaceuticals Inc.
XNAS: CURX
9,086
XNAS Volume

XNAS 14 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Curanex Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Curanex Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue Curanex Pharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Curanex Pharma Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of -5353.1% YoY.

Curanex Pharmaceuticals Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23
Operating Rev.
Cost Of Rev.
------------
Gross Profit
------------
⌄
3.33.23.110.10.10.10.100.10
Operating Profit
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
---
Profit Before Tax
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Tax
------------
⌄
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Diluted NI Avail to Com Stockholders Ann.
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Basic EPS
-2.4-2.2-2.4-0.8-0-0.1-0.2-0-0-0.1-0.4
Diluted EPS After ExtraOrdinary
-2.4-2.2-2.4-0.8-0-0.1-0.1-0-0-0.1-0.4
Number Of Shares End
1.41.41.41.31.41.41.42.12.81.42.12.1
Net Income Continuing Discontinued Operations
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Normalized Income
-3.3-3.1-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Interest Income
------------
Interest
---
Net Interest Income
---
EBIT
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
EBITDA
-3.3-3.1-3-0.9-0-0.1-0.1-0.1-0-0.1-0
Reconciled Cost Of Rev.
------------
Reconciled Depr.
000000
Profit From Continuing Operations
-3.3-3.2-3.1-1-0.1-0.1-0.1-0.1-0-0.1-0
Normalized EBITDA
-3.3-3.1-3-0.9-0-0.1-0.1-0.1-0-0.1-0
*All financials are in USD Million and price data in USD

Curanex Pharma Inc competitor comparison and performance snapshot within industry

Curanex Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • NEUTRAL

    Annual Revenue Curanex Pharma Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit Curanex Pharma Inc Annual Net Profit is $-4 Million which is growth of -1068.7% YoY.

Curanex Pharmaceuticals Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsTTMDec '25Dec '24Dec '23Dec '22
-
 0
Cost Of Rev. Ann.
-
 --0
Gross Profit Ann.
-
 --
Operating Exp. Ann.
-
10.64.20.300
Operating Profit Ann.
-
-10.6-4.2-0.3-0-0
-
-0-0---
Other Exp. Ann.
-
 0-0.1-
PBT Ann.
-
-10.5-4.2-0.4-0-0
Tax Ann.
-
 ----
⌄
-
-10.5-4.2-0.4-0-0
Diluted NI Avail to Com Stockholders Ann.
-
-10.5-4.2-0.4-0-0
EPS Ann.
-
 -3.4-0.3-0.4-0.4
Diluted EPS Ann.
-
 -3.4-0.3-0.4-0.4
Number Of Shares End
-
 1.41.42.1-
Total Exp. Ann.
247.6%
 4.20.300.1
Net Income Continuing Discontinued Operations Ann.
-
-10.5-4.2-0.4-0-0
Normalized Income Ann.
-
-10.5-4.2-0.3-0-0
Interest Income Ann.
-
 ----
Interest Ann.
-
00---
EBITDA Ann.
-
-10.3-4.1-0.4-0
Reconciled Cost Of Rev. Ann.
-
 --0
Reconciled Depr. Ann.
-
0.10.10
Profit From Continuing Operations Ann.
-
-10.5-4.2-0.4-0-0
Normalized EBITDA Ann.
-
-10.3-4.1-0.2-0
*All financials are in USD Million and price data in USD
Operating Exp. Ann.
1Y CHG
1300%

Curanex Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Curanex Pharma Inc Dec-2025 Total Shareholders Fund is $11 Million which is growth of 2129.3% YoY.

  • POSITIVE

    Total Assets Curanex Pharma Inc Dec-2025 Total Assets is $12 Million which is growth of 2135.8% YoY.

Curanex Pharmaceuticals Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsDec '25Dec '24Dec '23Dec '22
-
11.60.50.10
⌄
-
0.400
⌄
-
11.20.50.10
Total Capitalization Ann.
-
11.20.50.10
Tangible Assets Ann.
-
11.20.50.10
Working Capital Ann.
-
11.10.50.10
Invested Capital Ann.
-
11.20.50.10
Tangible Book Value Ann.
-
11.20.50.10
Borrowings Ann.
-
0.4---
Net Debt Ann.
-
----
Share Issued Ann.
0%
1.41.41.41.4
Number Of Shares End
-
1.41.42.1-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
2220%
2Y CAGR
977%
Total ShareHolders Funds Ann.
1Y CHG
2140%
2Y CAGR
958.3%

Curanex Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • NEUTRAL

    Book Value Per Share Curanex Pharma Inc Book Value Per Share is $10 which is growth of 0% YoY.

  • NEUTRAL

    ROE Curanex Pharma Inc ROE is 0% which is growth of 0% YoY.

Curanex Pharmaceuticals Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsDec '25Dec '24Dec '23Dec '22
RoA Ann. %
-
----
ROE Ann. %
-
----
ROIC %
-
----
OPM Ann. %
-
----77.81%
Inventory Turnover Ratio Ann.
-
----
Asset Turnover Ann. %
-
----
Working Capital Turnover Ann.
-
2.5
Quick Ratio Ann.
-
----
Current Ratio Ann.
-
----
Interest Coverage Ratio Ann.
-
----
LT Debt To Equity Ann.
-
----
*All financials are in USD Million and price data in USD

Curanex Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Curanex Pharma Inc Cash From Operating Activity is $-10 Million which is growth of -1787.1% YoY.

  • NEUTRAL

    Net Cash Flow Curanex Pharma Inc Net Cash Flow is $0 Million which is growth of 0% YoY.

Curanex Pharmaceuticals Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsDec '25Dec '24Dec '23Dec '22
-
-10.5-0.6
-
----
-
15.30.60.1
Cash Plus Cash Eqv. End Of Year Ann.
-
50.20.1
Net Increase In Cash Plus Cash Eqv.s Ann.
-
4.80.10.1
Cash Plus Cash Eqv. Begin Of Year Ann.
-
0.20.1
Income Tax Paid Supplemental Data Ann.
-
----
Interest Paid Supplemental Data Ann.
-
----
Capex Ann.
-
----
Issuance Of Capital Stock Ann.
-
15.70.60.1
Issuance Of Debt Ann.
-
----
Repayment Of Debt Ann.
-
----
Repurchase Of Capital Stock Ann.
-
----
Free Cash Flow Ann.
-
-10.5-0.6
*All financials are in USD Million and price data in USD
Cash from Financing Act. Ann.
1Y CHG
2450%
2Y CAGR
1136.9%